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PDB147
Why Physicians Do not folloW aacE/acE guiDElinEs in trEating 
qualifiED PatiEnts With t2DM: a survEy stuDy in thE unitED statEs
Qiu Y.1, Li Q.1, Tang J.2, Fan C.P.S.2, Li Z.2, Apecechea de Scheffer M.3, Hegar R.3, Shankar R.1, 
Engel S.S.1
1Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA, 2AscelpiusAnalytics Ltd., Hong Kong, 
Hong Kong, 3Kantar Health Germany, Munich, Germany
Objectives: To assess factors affecting physicians’ decision on why they did not 
initiate dual therapy to untreated Type 2 Diabetes Mellitus (T2DM) patients with 
A1C 7.6–9% per AACE/ACE recommendation. MethOds: Primary care physicians 
(PCPs) and specialists in the US were asked to provide medical chart reviews for 4 
patients who were diagnosed with A1C 7.6-9% and initiated with metformin mono-
therapy. Physicians rated 22 reasons on a 5-point Likert scale (1-most irrelevant; 
5-most relevant) on how relevant each reason was for them in treating a specific 
patient. Top 5 reasons ( ≥ 50% of physicians rating the reason as 4 or 5) were identi-
fied. Association of each reason on physician specialty or age was conducted using 
mixed-effect model controlling for physician and patient characteristics. Results: 
1,235 PCPs and 290 specialists participated the study and provided reviews for 5,995 
patients (3,009 young and 2,986 elderly). Four relevant reasons were related to phy-
sicians attitudes and beliefs toward metformin monotherapy and dual therapy: 
R1-“Metformin monotherapy is sufficient to improve glycemic control” (mean[sd]: 
3.66[1.1]); R2 - “Monotherapy is easier to handle than dual therapy” (3.53[1.2]); R3- “I 
believe that monotherapy and changes in lifestyle (e.g. physical activity and dietary 
change) are enough for hyperglycemia control” (3.47[1.1]); and R4- “I recommend 
monotherapy before considering dual therapy” (3.75[1.1]). One relevant reason was 
related to physicians’ perception of patients’ glycemic level: R5 -“Patient has mild 
hyperglycemia” ” (3.27[1.1]). PCPs rated the four reasons more relevant than special-
ists (estimate,[95% CI]) (R1: 0.18,[0.05,0.30]; R2: 0.37,[0.24,0.50]; R3: 0.33,[0.20,0.46]; 
R4: 0.36,[0.23,0.49]. All p< 0.01). Lowering age was also more relevant in the four 
reasons (R1: -0.04,[-0.06,-0.02]; R2: -0.03,[-0.05,-0.02]; R3: -0.02,[-0.03,0.00], R4: -0.06,[-
0.07,-0.04]. All p< 0.02). cOnclusiOns: Guideline non-concordance is related to 
physicians’ attitudes and beliefs toward the therapies and perception of A1C above 
8% as “mild”. The findings have implications for improving T2DM treatment quality.
PDB148
longituDinal PattErns of antiDiaBEtEs MEDication PrEscriPtion 
aMong PrivatEly insurED MEDicarE PatiEnts
Bae J.P, Peng X., Jiang D., Zagar A.
Eli Lilly and Company, Indianapolis, IN, USA
Objectives: To describe changing diabetes treatment pattern among the elderly 
type 2 diabetes (T2DM) patients during the past 7 years. MethOds: A large retro-
spective Medicare patient claims data (MarketScan® Medicare) was longitudinally 
analyzed from 2005 to 2011 to understand T2DM medication use trend. The study 
included 4 major oral antidiabetic medications (i.e., metformin (MET), sulphony-
lurea (SU), thiazolidinediones (TZD), and dipeptidyl peptidase 4 inhibitor (DPP-4)) 
plus injectables (insulin and glucagon-like peptide 1 (GLP-1)) and reported patterns 
of therapy regimens and trends over time. Results: The study identified 453,045 
patients with 1 year enrollment and with T2DM taking one or more antidiabetic 
medications in 2011, compared to 283,484 patients in 2005. The frequently used 
mono therapies in 2011 are MET (22.1%), insulin (12.0%) and SU (10.8%), followed 
by TZD (2.6%), DPP-4 (2.0%), GLP-1 (0.28%). The percentage of patients using MET 
monotherapy increased from 15.0% in 2005 to 22.1% in 2011, while the percentage 
of patients using SU alone decreased from 16.6% in 2005 to 10.8% in 2011. Patients 
taking DPP-4 only increased from 0.03% in 2006 to 2.0% in 2011. Among the combi-
nation therapies in 2011, the most popular one was MET+SU (12.2%), followed by 
MET+DPP-4 (2.9%), MET+SU+DPP-4 (2.8%), MET+TZD (2.8%) and MET+SU+insulin 
(2.3%). The percentage of patients taking any type of insulin rose by 3.4 on from 
24.7% in 2005 to 28.1% in 2011. cOnclusiOns: This study shows changing trends 
in different classes of diabetes medication in this large sample Medicare patients 
over time. Continuing research is needed to monitor anitdiabetic treatment pattern 
change in the future and to understand how these changes are helping to improve 
diabetes care and outcomes.
PDB149
MEDication aDhErEncE anD sWitching ratEs of PatiEnts With 
tEstostEronE rEPlacEMEnt thEraPy (trt) in thE unitED statEs
Puenpatom R.A., Ma L., Camper S.B.
Endo Pharmaceuticals Inc., Malvern, PA, USA
Objectives: To assess medication adherence and switching rates of testosterone 
replacement therapy (TRT) in the US. MethOds: We conducted a retrospective 
claims database study using the MarketScan® Commercial database from January 
2005 through December 2011. The study included men 18-65 years of age who 
had initiated TRT and were diagnosed with hypogonadism or hypogonadotropic 
hypogonadism (ICD-9-CM: 257.3 and 257.4). A minimum of 6 months continuous 
enrollment before and 12 months after the TRT index date was required. Adherence 
was measured by the Mediation Possession Ratio (MPR) and the Proportion of Days 
Covered (PDC), with the adherence rate defined as MPR≥ 0.8. The rate of the first 
switching was summarized by TRT formulation. Results: Of 106,039 patients with 
hypogonadism, the mean MPR and the mean PDC of any TRT during the 360 days 
study period was 0.47 and 0.44, respectively. The overall adherence rate over 12 
months was 21.4% ranging from 28% (pellets), 19.9% (SAIs), 17.7% (gels), 7.8% (buc-
cal), and 6.6% (patch), respectively. Similarly, the average PDCs were significantly 
higher for pellets (0.59) compared to gels (0.43), SAIs (0.39), buccal (0.28), and patch 
(0.27) (P< 0.001). About 13% (n = 13,577) of patients switched from their initial therapy 
to a different TRT formulation. Patients starting with patch were most likely to 
switch to a different formulation (39.3%), followed by patients with SAIs (12.1%), pel-
lets/buccal (12.0%), and gels (10.3%). cOnclusiOns: Our study showed low adher-
ence rates of testosterone replacement therapy among hypogonadism patients. The 
adherence for patients starting on the long-acting testosterone formulation such 
Simulations estimated 1- and 3-year HbA1c progression for 1000 hypothetical 
T2DM patients (average 7 (SE 5.1) years post-diagnosis) to obtain the propor-
tion meeting criteria for < 7%, < 8% and > 9% thresholds by bootstrapping the UK 
Prospective Diabetes Study (UKPDS) 68 equation. UKPDS68 accounts for time, 
HbA1c in the prior year, drug treatment effect, and baseline A1c. Parameter values 
for duration of diabetes, baseline HbA1c, and treatment effect were selected from 
distributions around the mean, and mean values of the latter two were system-
atically varied to approximate different populations and effects. Results: By 1 
year, all NCQA requirements are met when treating patients with alo-pio if aver-
age baseline HbA1c is ≤ 8%. At 3 years, all requirements are met in patients with 
baseline HbA1c ≤ 7.2%, though 8% and 9% threshold requirements are feasible with 
higher baseline HbA1c. Using a more realistic thiazolidinedione durability assump-
tion (annual rosiglitazone HbA1c increase) instead of UKPDS68, all thresholds are 
met at 1 year ≤ 8% baseline HbA1c, and at 3 years with ≤ 7.4% baseline HbA1c. The 
7% and 8% requirements are met with ≤ 8.2% baseline HbA1c at 1 year; at 3 years, 
8% and 9% thresholds can be met with baseline HbA1c ≤ 8-8.2%. cOnclusiOns: 
The simulations show that clinical thresholds can be met at 1 and 3 years, indi-
cating that alo-pio can be considered for treating an appropriate population from 
an ACO perspective.
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rElEvancE of clinical trials to inforM hta: DisParity BEtWEEn 
hta EviDEncE rEquirEMEnts anD PuBlishED rcts in tyPE 2 DiaBtEtEs 
MEllitus
King D.T.1, Trautmann M.2, Sabater J.3, Pahor A.4, Shaw J.W.5, Grandy S.6, Budd D.3,  
Mitchell S.A.1
1Abacus International, Bicester, UK, 2Diabetes Research, Hamburg, Germany, 3Bristol-Myers 
Squibb EMEA SARL, Paris, France, 4Astra Zeneca GmbH, Wedel, Germany, 5Bristol-Myers Squibb, 
Princeton, NJ, USA, 6AstraZeneca LP, Wilmington, DE, USA
Objectives: Health technology assessment (HTA) agencies and reimbursement 
authorities typically require evidence from randomised controlled trials (RCTs) to 
assess the comparative effectiveness of drugs. For example, for an assessment of 
the GLP-1 receptor agonist exenatide for management of Type 2 diabetes mellitus 
(T2DM), the German Federal Joint Committee (G-BA) pre-specified comparators of 
interest for short- (Byetta®) and long-acting exenatide formulations (Bydureon®) 
in seven indications. The aim of this research was to assess the availability of 
direct or indirect evidence for the benefit of exenatide to support an HTA sub-
mission to the G-BA. MethOds: A systematic literature review was conducted 
to identify RCTs comparing exenatide with pharmacological interventions in 
patients with T2DM. Electronic databases (Medline, Embase, Cochrane library: 
accessed October 2013) and clinical trial registries were interrogated. Results: Of 
twenty-nine Byetta® RCTs identified, twenty-seven were inappropriate to provide 
evidence to the G-BA for the following reasons: use of a non-pre-defined compara-
tor (n= 13), background treatment not requested by G-BA (n= 12), or administration 
of a non-licenced Byetta® dose (n= 2). The remaining two studies provided direct 
evidence for two indications. None of the eight Bydureon® RCTs identified were 
appropriate for direct analysis: use of a non-G-BA-required background treat-
ment (n= 7) or comparator (n= 1). For the five indications where no direct evidence 
was available, a single RCT investigating Bydureon® was identified which could 
potentially be used in an indirect comparison against a G-BA required compara-
tor. cOnclusiOns: Despite identification of over thirty RCTs investigating exena-
tide, most of the available evidence would not be considered appropriate by the 
G-BA to assess the benefit of exenatide despite having formed the basis for regula-
tory approval. Regulatory and HTA agencies, reimbursement authorities, and the 
pharmaceutical industry should be aligned on appropriate RCT design to ensure 
the generation of relevant evidence, although this may be challenging given the 
dynamic diabetes treatment environment.
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PatiEnt aWarEnEss of hBa1c in tyPE 2 DiaBEtEs: trEnDs anD 
iMPlications for hEalth outcoMEs
Annunziata K.1, DiBonaventura M.2, Sternbach N.2
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, New York, NY, USA
Objectives: Maintaining glycemic control for patients with type 2 diabetes (T2D) 
is associated with a reduced risk of future complications. Proper patient aware-
ness of HbA1c is important to facilitate adherence and improve outcomes. This 
study profiles how HbA1c awareness has changed over time and the consequences 
of poor awareness. MethOds: Data from the 2006-2013 US National Health and 
Wellness Survey (NHWS) were used in the analysis (Ns = 62,834 to 75,000 in each 
year). The NHWS is an annual, patient-reported, cross-sectional survey fielded to 
match the demographic characteristics of the US adult population. Patient aware-
ness of their HbA1c levels (i.e., a reported value vs. a “don’t know” response) was 
examined each year. Differences between those who were aware versus unaware 
were made with respect to health status (using the SF-36v2), work productivity 
loss (using the WPAI-GH), and health care resource in a series of regression models 
controlling for demographics and health characteristics. Results: Awareness of 
HbA1c levels improved from 26.6% (in 2006) to 56.4% (in 2013). In 2013, patients who 
are aware (n= 4658) were more likely to be older (60.5 vs. 57.2 years), non-Hispanic 
white (71.4% vs. 61.1%), treating with oral/insulin/non-insulin injectable (87.8% vs. 
76.1%), and more likely to have had diabetic complications compared with those 
who were unaware (n= 3040; all p< .05). Holding demographics and health history 
constant, lack of awareness was associated with poorer health utilities (0.70 vs. 0.68), 
more overall work impairment (17.9% vs. 20.8%), and more hospitalizations in the 
past six months (0.26 vs. 0.22), among other outcomes (all p< .05). cOnclusiOns: 
Awareness of HbA1c has increased over time, though appears disproportionately 
higher among patients of high socioeconomic status and higher risk (i.e., those with 
complications and using insulin). Awareness was also independently associated 
with poorer health outcomes suggesting improved patient education may have 
significant societal benefits.
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regulatory reviews faster than the EMA while beginning regulatory review first in 
each case. Three of the four regulatory decisions in which the FDA was slower were 
outliers in terms of approval time. Additionally, when looking at the median, the 
FDA approved these moieties 77 days faster than the EMA while Downing’s findings 
only showed a 44-day differential. This was expected because the analysis included 
the EC decision takes about 2 months on average. cOnclusiOns: After updating 
the data, restricting it to a particular subset of diabetes treatments, and altering 
the EMA regulatory endpoint, Downing et al’s findings not only still hold true, but 
become even more pronounced.
PDB153
DElayED trEatMEnt MoDifications for PatiEnts With tyPE 2 DiaBEtEs 
MEllitus (t2DM) With vEry Poor glycEMic control
Schwab P.1, Saundankar V.1, Bouchard J.R.2, Moretz C.1, Baltz J.3
1Comprehensive Health Insights, Louisville, KY, USA, 2Novo Nordisk, Inc., Princeton, NJ, USA, 
3Humana Inc., Louisville, KY, USA
Objectives: Risk of cardiovascular disease, retinopathy, nephropathy, and neu-
ropathy increases substantially when HbA1c> 7% (suboptimal glycemic control), but 
timely therapy intensification may reduce risk. When HbA1c> 9% (very poor control) 
AACE recommends that triple therapy (asymptomatic patients) or insulin (sympto-
matic patients) be initiated to reach HbA1c≤ 6.5% for patients without concurrent 
illness and at low hypoglycemic risk. Clinical inertia (failure to intensify therapy in 
a timely manner) leads to poor glycemic control. The objective of this study was to 
examine time to treatment modifications in patients with HbA1c≥ 9%. MethOds: 
Medical, laboratory, and pharmacy claims data for Humana’s fully insured commer-
cial and Medicare membership were used for this study. Patients with T2DM with 
first HbA1c≥ 9% date (index-date) between Jan 1, 2008–Dec. 31, 2009 were identified. 
Baseline characteristics were obtained within 12 months preceding the index-date. 
Treatment modification was defined as addition or switch of an antidiabetic drug 
class. Study outcome (delay in treatment modification) was assessed as the days 
until modification within the 36-months post-index period. Results: There were 
8,464 patients identified (mean age 66 years, 48% male, 82% from the southern US, 
mean Deyo-Charlson Comorbidity Index 2.54, mean Diabetes Complications Severity 
Index 2.17). Approximately 83% of patients experienced modification within 36 
months; 47% within 90 days of HbA1c≥ 9% index date, 7% between 91-180 days, 5% 
between 181-365 days, while 24% were > 365 days. Around 20% of patients received 
insulin as a modification. Although the proportion of patients receiving triple 
therapy (≥ 3 classes) was still low (23%) at 12 months post-index, it increased from 
10% at baseline. cOnclusiOns: Many patients in poor control receive insufficient 
therapy as recommended by treatment guidelines. Even though additional agents 
were added for some patients, those receiving insulin or triple therapy were low. For 
patients with HbA1c≥ 9%, prompt treatment intensification is needed to improve 
glycemic control and limit complications.
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cost iMPlications of Early Discontinuation anD rEstart of insulin 
in thE trEatMEnt of tyPE 2 DiaBEtEs MEllitus
Ascher-Svanum H.1, Lage M.J.2, Perez M.1, Reaney M.D.3, Lorraine J.4, Rodriguez A.5, Treglia M.2
1Eli Lilly and Company, Indianapolis, IN, USA, 2HealthMetrics Outcomes Research, Bonita Springs, 
FL, USA, 3Eli Lilly and Company, Windlesham, Surrey, UK, 4Eli Lilly Canada, Toronto, ON, Canada, 
5Eli Lilly Spain, Madrid, Spain
Objectives: This study examined different types of medical costs associated with 
early discontinuation (ED) of insulin therapy and with restarting of insulin among 
ED patients in the treatment of type 2 diabetes mellitus (T2DM). MethOds: Truven’s 
Health Analytics Commercial Claims and Encounters database from 1/1/08 through 
12/31/11 were utilized. ED was defined as discontinuation of insulin therapy for at 
least 30 days in the first 90 days post initiation. Generalized linear models with log-
link were used to examine the association between ED and total medical costs, acute 
care (hospitalization and emergency room) costs, outpatient costs, diabetes-related 
drug costs and all-cause drug costs. Among ED patients, the association between 
restarting insulin therapy and costs were also examined. Analyses controlled for 
patient characteristics, index medication prescribed, patient general health, comor-
bidities, prior resource utilization, and prior medication utilization. Results: Most 
(82% of 74,399) individuals discontinued insulin therapy in the first year post initia-
tion and 75% of these patients were ED. Compared to non-ED, ED was associated 
with 9.6% higher acute care costs (P= 0.0003), while outpatient costs, diabetes-related 
drug costs, all-cause drug costs and total medical costs were all significantly lower 
among ED patients. Among the ED cohort, 90% restarted therapy over the post-
period, with 53% restarting within 4 months. Compared to non-restart, the restart of 
insulin therapy after ED was associated with 11.3% higher acute care costs (P= 0.033), 
24.0% higher outpatient costs (P< 0.001), 80.2% higher all-cause drug costs (P< 0.001, 
and 30.3% higher total medical costs (P< 0.001). cOnclusiOns: Current findings 
suggest that during the first three months following initiation of insulin therapy 
for T2DM, the ED of insulin therapy and its restart are associated with higher acute 
care costs. Such costs are often considered avoidable or modifiable costs and tend 
to signal poorer long-term treatment outcomes.
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national PattErns in PrEscriPtion MEDication trEatMEnt for 
DiaBEtEs: 2002-2010
Yuan J., Lu K., Wu J.
South Carolina College of Pharmacy – USC Campus, Columbia, SC, USA
Objectives: To compare recent trends in treatment pattern for diabetes between 
2002 and 2010. MethOds: A cross-sectional study of expenditures was carried 
for representative sample of civilian, noninstitutionalized U.S individuals with 
diabetes from the Medical Expenditure (MEPS) 2002-2010. Expenditures include 
all sources of payment for oral anti-diabetic medications, insulin, and non-insulin 
injectables. We inflated 2002 dollar values to 2010 values using the consumer price 
index. Results: From 2002 to 2010, the estimated number of persons reporting 
as pellets was higher than those with other formulations. Patients starting with a 
patch demonstrated the highest switching rate compared to other formulations.
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PattErns of MEDication usE in thE onE yEar folloWing initiation of 
DPP-4 inhiBitors in thE unitED statEs
Radawski C., Nelson D.R., Nyhuis A., Mitchell B., Johnston J.A.
Eli Lilly and Company, Indianapolis, IN, USA
Objectives: DPP-4 inhibitors produce a modest improvement in HgbA1C with 
relatively few adverse effects. Little is known about the characteristics and treat-
ment patterns of patients receiving DPP-4 inhibitors in the US. The objectives of 
the current study were to characterize patients prescribed DPP-4 inhibitors and 
examine patterns of anti-diabetic medication use in the one year following their 
initiation. MethOds: Data were obtained from Humedica’s National Electronic 
Health Record-Derived Longitudinal Patient-Level Database (2007–2011). The study 
cohort included all adult patients with T2DM who received a first prescription for a 
DPP-4 inhibitor during the study period and who had at least one HgbA1C value at 
baseline. Baseline patient demographics, clinical characteristics and anti-diabetic 
medication use in the one-year follow-up period were assessed. Cox proportional 
hazard models were used to assess independent predictors of the aggregate out-
come of switching or augmentation. Results: Of the 8700 patients in the study 
cohort, 84% were older than 50, and 52% were female; the mean BMI was 34.4 and 
mean HgbA1c at baseline was 7.81%. Overall, 2226 (25.6%) patients switched or 
augmented therapy within the first year following DPP-4 inhibitor initiation after 
a mean of 6.1 months; the most frequently observed patterns included a switch 
to another oral agent (n= 1791, 20.6%) or to insulin (n= 306, 3.5%). Higher baseline 
HgbA1C (HR 1.20 [95% CI 1.14-1.26] for HgbA1C > 9% vs. < 7%) and higher BMI (HR 
1.11 [95% CI 1.06-1.16] for BMI ≥ 30 vs. 25-29) predicted higher rates of switching/
augmentation, while female gender (HR 0.92 [95% CI 0.89-0.95]) and younger age 0.42 
[95% CI 0.22-0.81]) predicted lower rates. cOnclusiOns: In this US cohort, change 
in anti-diabetic treatment was relatively uncommon in the one year following ini-
tiation of a DPP-4 inhibitor. Baseline characteristics including HgbA1C, BMI and 
demographics can be used to inform the likelihood of switching or augmentation.
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Evaluation of association BEtWEEn DiaBEtEs rElatED quality 
MEasurE achiEvEMEnt anD DiaBEtEs coMPlications in a MEDicarE 
aDvantagE PoPulation
Ellis J.J.1, Bouchard J.R.2, Saundankar V.1, Moll K.1, Baltz J.3, Meah Y.3, Moretz C.1
1Comprehensive Health Insights, Louisville, KY, USA, 2Novo Nordisk Inc., Plainsboro, NJ, USA, 
3Humana Inc., Louisville, KY, USA
Objectives: Centers for Medicare and Medicaid Services (CMS) assess the per-
formance of health insurance plans using quality of care measures. This study 
assessed achievement of 8 diabetes-related quality measures at the patient 
level and examined whether achievement was associated with fewer complica-
tions. MethOds: Claims and member-level quality data between January 2010 
and December 2011 were obtained from a Medicare Advantage Prescription Drug 
Insurance provider. Patients with type 1 or type 2 diabetes on the index date 
(January 1, 2011) and with 12 months of pre- and post-index continuous enroll-
ment were included. Quality of care and diabetes complications were assessed 
during the post-index year. The impact of quality metric achievement on new or 
worsening diabetes complications was assessed with a logistic regression model, 
which adjusted for baseline characteristics. Results: Cohort size ranged from 
159,454 to 4,464, depending on the quality measure and patient-level data avail-
ability. Most patients (> 80%) achieved LDL-C screening, nephropathy assessment, 
and medication adherence standards. Over 99% of patients met dosing standards 
for biguanides, sulfonylureas, and thiazolidinediones. Eye screening and use of 
appropriate anti-hypertensive treatments had lower achievement levels (50.3% 
and 54.2%, respectively). A majority (61%) of patients achieved HbA1c< 9%; 29% of 
patients achieved LDL-C control < 100mg/dl. Logistic regression estimates showed 
that failure to reduce HbA1c below 9% statistically significantly increased the 
risk of new or worsening diabetes complications [(OR, 1.12 (95% CI, 1.10-1.15); 
p< 0.0001)] as did failure to use anti-hypertensive treatment [(OR, 1.40, (95% CI, 
1.24-1.59); p< 0.0001]. cOnclusiOns: Data from a 1-year observation period sug-
gests that attainment of CMS diabetes quality metrics was associated with lower 
new or worsening complication risk. Since the full impact of improved care may 
not be properly assessed within such a short time, follow-up longitudinal studies 
would shed light on the long-term impact of achieving quality measures.
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a rEgulatory coMPararison of non-insulin DEPEnDEnt tyPE ii 
DiaBEtEs Drug aPProvals in thE unitED statEs anD EuroPEan union
Sanchez D.P., Rubinstein J., Rubinstein E., Sliman R., Daniel K., Ho Y.S.
Context Matters, Inc., New York, NY, USA
Objectives: In 2012, Downing et al published a novel study in the NEJM that com-
pared the speed of regulatory agencies between 2001-2010, which demonstrated the 
FDA’s relative quickness. This paper narrows the scope to new non-insulin depend-
ent type II diabetes drugs approved by the EMA and FDA (using their respective 
websites) during 2005-2013, accounting for new drug approvals and legal updates 
to regulatory systems in a disease condition that has faced a plethora of regu-
latory challenges. MethOds: Unlike Downing, this study looks at the European 
Commission’s (EC) decision, instead of the Committee for Medical Products for 
Human Use’s (CHMP) recommendation. A Marketing Authorization is issued upon 
EC decision, making it analogous with the data captured surrounding the FDA’s 
approval process. Additionally this analysis looks at the date submitted to the FDA 
and EMA as well as the approval date. The data consists of 12 non-insulin dependent 
moieties approved between 2005 and 2013. Results: Out of the 12 new treatments, 
10 were approved first by the FDA (83%). Additionally, the FDA began reviews before 
the EMA with a median time of 126.5 days. The FDA also completed 8 of the 12 
